
5.50.037

Section:	Prescription Drugs	Effective Date:	April 1, 2024
Subsection:	Gastrointestinal Agents	Original Policy Date:	November 10, 2023
Subject:	Velsipity	Page:	1 of 6

Last Review Date: March 8, 2024

Velsipity

Description

Velsipity (etrasimod)

Background

Velsipity (etrasimod) is a sphingosine-1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1, 4, and 5 (S1P_{1,4,5}). Velsipity partially and reversibly blocks the capacity of lymphocytes to egress from lymphoid organs, reducing the number of lymphocytes in peripheral blood. The mechanism by which Velsipity exerts therapeutic effects in ulcerative colitis is unknown but may involve the reduction of lymphocyte migration into the intestines (1).

Regulatory Status

FDA-approved indication: Velsipity is a sphingosine 1-phosphate receptor modulator indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adults (1).

Before initiation of treatment with Velsipity, the following should be assessed: (1)

- Complete blood count (CBC) – Obtain a recent CBC including lymphocyte count
- Cardiac evaluation – Obtain an electrocardiogram (ECG) to determine whether preexisting conduction abnormalities are present
- Liver function tests – Obtain recent (i.e., within the last 6 months) transaminase and bilirubin levels
- Ophthalmic assessment – Obtain a baseline evaluation of the fundus, including the macula, near the start of treatment
- Vaccination – Test patients for antibodies to varicella zoster virus (VZV) before initiating Velsipity; VZV vaccination of antibody-negative patients is recommended prior to

Section:	Prescription Drugs	Effective Date:	April 1, 2024
Subsection:	Gastrointestinal Agents	Original Policy Date:	November 10, 2023
Subject:	Velsipity	Page:	2 of 6

commencing treatment with Velsipity. If live attenuated vaccine immunizations are required, administer at least 4 weeks prior to initiation of Velsipity.

- Skin examination – Obtain a skin examination prior to or shortly after initiation. Suspicious skin lesions should be promptly evaluated

Velsipity is contraindicated in patients who in the last 6 months experienced a myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization, or Class III/IV heart failure (1).

Velsipity is also contraindicated in patients with Mobitz type II second-degree or third degree atrioventricular (AV) block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker (1).

The safety and effectiveness of Velsipity in pediatric patients less than 18 years of age have not been established (1).

Related policies

Zeposia

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Velsipity may be considered **medically necessary** if the conditions indicated below are met.

Velsipity may be considered **investigational** for all other indications.

Prior-Approval Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

1. Moderately to severely active Ulcerative Colitis (UC)

Section:	Prescription Drugs	Effective Date:	April 1, 2024
Subsection:	Gastrointestinal Agents	Original Policy Date:	November 10, 2023
Subject:	Velsipity	Page:	3 of 6

- a. Inadequate treatment response, intolerance, or contraindication to at least **ONE** conventional therapy option (see Appendix 1)
- b. **NOT** to be used in combination with a biologic DMARD or targeted synthetic DMARD for UC (e.g., Entyvio, Humira, Simponi, Stelara, Xeljanz)
- c. Patient **MUST** have tried the preferred product(s) (see Appendix 2) unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)

AND ALL of the following:

1. Baseline evaluations of **ALL** of the following have been done or will be done prior to starting therapy with Velsipity:
 - a. Complete blood count (CBC), including lymphocyte count
 - b. Electrocardiogram (ECG)
 - c. Liver function tests (LFTs)
2. Heart rate \geq 50 bpm
3. **NO** history (within the last 6 months) of myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure
4. **NO** presence of Mobitz Type II second-degree or third degree AV block, sick sinus syndrome, or sino-atrial block, unless patient has a pacemaker
5. **NO** significant QTc prolongation (QTcF \geq 450 msec in males, \geq 470 msec in females)
6. **NO** severe untreated sleep apnea
7. Patients with a history of uveitis and/or diabetes **ONLY**: will have an ophthalmic evaluation of fundus, including the macula, prior to initiation of therapy
8. **NOT** given concurrently with live vaccines

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

5.50.037

Section:	Prescription Drugs	Effective Date:	April 1, 2024
Subsection:	Gastrointestinal Agents	Original Policy Date:	November 10, 2023
Subject:	Velsipity	Page:	4 of 6

1. Ulcerative Colitis (UC)
 - a. Condition has improved or stabilized
 - b. **NOT** to be used in combination with a biologic DMARD or targeted synthetic DMARD for UC (e.g., Entyvio, Humira, Simponi, Stelara, Xeljanz)
 - c. Patient **MUST** have tried the preferred product(s) (see Appendix 2) unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)

AND ALL of the following:

1. Heart rate \geq 50 bpm
2. **NO** history (within the last 6 months) of myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure.
3. **NO** presence of Mobitz Type II second-degree or third degree AV block, sick sinus syndrome, or sino-atrial block, unless patient has a pacemaker
4. **NO** significant QTc prolongation (QTcF \geq 450 msec in males, \geq 470 msec in females)
5. **NO** severe untreated sleep apnea
6. **NOT** given concurrently with live vaccines

Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Quantity 90 tablets per 90 days

Duration 12 months

Prior – Approval *Renewal* Limits

Same as above

Rationale

5.50.037

Section:	Prescription Drugs	Effective Date:	April 1, 2024
Subsection:	Gastrointestinal Agents	Original Policy Date:	November 10, 2023
Subject:	Velsipity	Page:	5 of 6

Summary

Velsipity (etrasimod) is a sphingosine-1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1, 4, and 5. Velsipity blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which Velsipity exerts therapeutic effects in ulcerative colitis is unknown but may involve the reduction of lymphocyte migration into the intestines. The safety and effectiveness of Velsipity in pediatric patients less than 18 years of age have not been established (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Velsipity while maintaining optimal therapeutic outcomes.

References

1. Velsipity [package insert], New York, NY: Pfizer Inc.; November 2023.

Policy History

Date	Action
November 2023	Addition to PA
March 2024	Annual review and reference update

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 8, 2024 and is effective on April 1, 2024.

Section: Prescription Drugs	Effective Date: April 1, 2024
Subsection: Gastrointestinal Agents	Original Policy Date: November 10, 2023
Subject: Velsipity	Page: 6 of 6

Appendix 1 – List of Conventional Therapies

Conventional Therapy Options
1. Mild to moderate disease - induction of remission: a. Oral budesonide, oral mesalamine b. Alternatives: metronidazole, ciprofloxacin
2. Mild to moderate disease - maintenance of remission: a. Azathioprine, mercaptopurine b. Alternatives: oral budesonide, methotrexate intramuscularly (IM)
3. Moderate to severe disease - induction of remission: a. Prednisone, methylprednisolone intravenously (IV) b. Alternatives: methotrexate IM
4. Moderate to severe disease - maintenance of remission: a. Azathioprine, mercaptopurine b. Alternative: methotrexate IM
5. Perianal and fistulizing disease - induction of remission c. Metronidazole ± ciprofloxacin
6. Perianal and fistulizing disease - maintenance of remission d. Azathioprine, mercaptopurine e. Alternative: methotrexate IM

Appendix 2 - List of Preferred Products

Diagnosis	Standard Option/Basic Option Preferred Products	Blue Focus Preferred Products
Ulcerative colitis (UC)	*must try TWO preferred products: Humira Rinvoq Stelara (SC)	Humira